• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Research & Development

Minnesota doc creates $50 EpiPen alternative

September 16, 2016 By Sarah Faulkner

AllergyStop

A Minnesota doctor reportedly created a $50 EpiPen alternative and is trying to raise money to bring it to patients. Dr. Douglas McMahon, who has severe food allergies, told CBS Minnesota that he was hesitant to carry his EpiPen because it was so bulky. As a certified allergy specialist, McMahon began constructing an alternative in his […]

Filed Under: Drug-Device Combinations, Research & Development Tagged With: AllergyStop, Mylan

High-capacity nanoparticle holds potential for targeted cancer therapies

September 15, 2016 By Sarah Faulkner

High-capacity nanoparticle holds potential for targeted cancer therapies

Chemists from the Mass. Institute of Technology developed a nanoparticle that they can pack with 3 or more drugs to create custom combination therapies for cancer, according to a study published this week in the Journal of the American Chemical Society. The team also revealed that cisplatin, a powerful anti-cancer drug, doesn’t work using the […]

Filed Under: Drug-Device Combinations, Oncology, Research & Development Tagged With: Mass. Institute of Technology

AstraZeneca, Bespak ink deal for metered-dose inhaler

September 12, 2016 By Sarah Faulkner

Consort Medical's Bespak, Astra Zeneca

AstraZeneca (NYSE:AZN) said last week that it inked a multi-year commercial supply deal with Consort Medical (LON:CSRT) subsidiary Bespak for its pressurized metered-dose inhaler technology. Bespak will supply inhaler valves and actuators for use with AstraZeneca’s inhaled aerosol treatment for chronic obstructive pulmonary disease. AstraZeneca won FDA approval in April for the aerosol, Bevespi Aerosphere […]

Filed Under: Drug-Device Combinations, Research & Development Tagged With: AstraZeneca plc, Consort Medical

DelMar, Accurexa ink deal for chemotherapy combo

September 7, 2016 By Sarah Faulkner

DelMar Pharmaceuticals and Accurexa  said today that they inked a deal to collaborate on a combination chemotherapy for local treatment of brain cancer. The agreement calls for DelMar to supply the drug dianhydrogalactitol (VAL-083) as part of a combination with another chemotherapeutic, either temozolomide or carmustine, for local delivery to the tumor via Accurexa’s ACX-31 implantable […]

Filed Under: Drug-Device Combinations, Neurological, Oncology, Pharmaceuticals, Research & Development Tagged With: Accurexa Inc., DelMar Pharmaceuticals

GlaxoSmithKline’s triple combo with Innoviva tops Symbicort Turbohaler in COPD

September 7, 2016 By Sarah Faulkner

GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) yesterday touted results from a Phase III study investigating the triple-combination therapy fluticasone furoate/umeclidnium/vilanterol for patients with chronic obstructive pulmonary disease. The 1,810-patient Fulfil study is a randomized, double-blinded trial comparing once-daily FF/UMEC/VI against AstraZeneca‘s (NYSE:AZN) Symbicort Turbohaler dry powder inhaler, a twice-daily combination of budesonide and formoterol. Patients in the FF/UMEC/VI […]

Filed Under: Clinical Trials, Drug-Device Combinations, Research & Development Tagged With: AstraZeneca plc, GlaxoSmithKline plc, Innoviva

MIT, Singapore Univ. dev 3-D-printed structures that “remember” their shapes

August 26, 2016 By drugdelivery

By Sarah Faulkner Engineers from MIT and Singapore University of Technology and Design are using light to create 3D structures that remember their shape when triggered by external stimuli like temperature. These structures, also known as shape-memory polymers, could be useful as delivery vessels for drugs in the human body. Get the full story at […]

Filed Under: Drug-Device Combinations, Materials Testing, Research & Development Tagged With: Massachusetts Institute of Technology

BioCorRx launches R&D program for anti-addiction naltrexone drug-device combo

July 14, 2016 By Fink Densford

Anti-addiction developer BioCorRx said today it launched a research & development initiative as it seeks FDA approval for its naltrexone implant designed to treat opioid and alcohol addictions. The implant slowly releases naltrexone, a non-addictive opioid antagonist that can reduce physical cravings and block some of the effects of alcohol and opioids, the Los Angeles-based […]

Filed Under: Drug-Device Combinations, Research & Development Tagged With: BioCorRx

Unilife & Amgen finalize $75m co-development deal

February 22, 2016 By Fink Densford

Unilife (NSDQ:UNIS) said today it finalized a $75 million collaborative deal with Amgen (NSDQ:AMGN) for injectable drug delivery systems, a deal the companies have been working out for the past month. The deal includes licensing, investment, development and supply agreements and is centered around Unilife’s prefilled customizable wearable injectors, according to an SEC filing from the York, […]

Filed Under: Business/Financial News, Drug-Device Combinations, Research & Development Tagged With: Amgen, Unilife Corp.

Diabetes: Medtronic furthers the quest for an artificial pancreas

June 15, 2015 By Fink Densford

Medtronic (NYSE:MDT) and Intarcia Therapeutics were in the spotlight at the American Diabetes Assn.’s annual scientific sessions conference in Boston last week, revealing new medical device developments in the fight against diabetes. Medtronic took center stage, announcing new developments for its artificial pancreas program, touting positive data from a user study of its MiniMed 640g and revealing plans to collaborate […]

Filed Under: Clinical Trials, Drug-Device Combinations, Research & Development Tagged With: Becton Dickinson, GI Dynamics, Glytec, Intarcia Therapeutics, Medtronic, Valeritas Inc.

Delcath's Chemosat gives terminal cancer patients several more months of disease-free life

September 26, 2011 By drugdelivery

Delcath Chemosat

Delcath Systems Inc.’s (NSDQ:DCTH) Chemosat organ-targeting chemotherapy system extended the lives of terminal eye cancer patients by several months without disease progression, researchers said.

Melanoma of the eye often spreads to the liver, generally killing a patient in 1 to 2 months, according to a press release. Patients who received targeted treatment to saturate the liver lived an average of 8.1 months, compared to 1.6 months for patients receiving the best alternative care.

Filed Under: Drug-Device Combinations, Research & Development Tagged With: Clinical Trials, Delcath Systems Inc.

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 45
  • Page 46
  • Page 47
  • Page 48
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS